SCP
NVO

Syntal Capital Partners’s Novo Nordisk NVO Stock Holding History

Syntal Capital Partners’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-12,626
Closed -$300K – 190
2014
Q3 		$300K Sell
12,626
-9,860
-44% -$227K 0.15% 36
2014
Q2 		$515K Buy
22,486
+11,244
+100% +$248K 0.25% 32
2014
Q1 		$256 Buy
+11,242
New +$240K 0.15% 54

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Syntal Capital Partners's NVO Position: Q4 2014 in Review

Syntal Capital Partners sold out of Novo Nordisk (NVO) in Q4 2014, closing a stake of 12,626 shares — an estimated $300K sold.

Syntal Capital Partners first reported a position in NVO in Q1 2014 and held it in 3 quarters. The position peaked at $515K in Q2 2014. 500 funds tracked by Wall St. Rank hold NVO as of Q4 2014.

  • Syntal Capital Partners reported no remaining Novo Nordisk position as of Q4 2014 after selling out during the quarter.
  • Syntal Capital Partners sold 12,626 Novo Nordisk shares in Q4 2014, an estimated $300K.
  • Syntal Capital Partners first reported a position in Novo Nordisk in Q1 2014 and held it in 3 quarters.
  • Syntal Capital Partners's Novo Nordisk position peaked at $515K in Q2 2014.
  • 500 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2014.

Based on Syntal Capital Partners's 13F filing for Q4 2014, filed 6 Feb 2015.